Gibson Christopher 4

What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), reported several transactions on May 7, 2026. He sold 40,000 shares in an open-market sale at $3.37 each for proceeds of $134,800. The filing also shows conversions of derivative securities (60,000 shares acquired at $0.00; a separate derivative conversion recorded as a disposition for 60,000 shares) and a gift of 20,000 shares. The conversions relate to Class B common stock that is convertible into Class A common stock (see footnote F1).

Key Details

• Transaction date: 2026-05-07 (Form filed 2026-05-08 — timely).
• Open-market sale: 40,000 shares @ $3.37 = $134,800 (Sale code S). This sale was made pursuant to a Rule 10b5‑1 trading plan (footnote F2).
• Derivative conversions: 60,000 shares acquired @ $0.00 (code C) and a separate C-coded disposition of 60,000 shares @ $0.00 (reported as a derivative transaction). Footnote F1: Class B shares are convertible into Class A shares at the holder’s option.
• Gift: 20,000 shares (code G) @ $0.00. Gifts typically reflect personal/estate planning and are not a market sentiment signal.
• Holdings/vehicles: Some shares are held by entities/trusts of which Gibson is a member/manager or trustee (LAHWRAN-3 LLC, LAHWRAN-4 LLC, Gibson Family Trust — footnotes F3–F5).
• Shares owned after transaction: Not stated in the provided excerpt.

Context

• The 10b5‑1 note indicates the sale was executed under a pre-established trading plan, which often means the sale was pre-scheduled rather than a discretionary trade.
• Conversions of derivative securities here reflect converting Class B common into Class A common (no cash paid), not a cash purchase.
• The gift of 20,000 shares is a personal transfer and should not be interpreted as an economic “sale” signal.